0
selected
-
1.
Clinical effects of treatment with Tirofiban on patients with high-risk NSTE-ACS after PCI.
Wei, P, Huang, YJ, Zuo, XH, Zhang, YG, Tao, ZQ, Qiu, CR, Zhang, Q, Yang, XJ, Fu, Q
European review for medical and pharmacological sciences. 2016;(7):1356-9
Abstract
OBJECTIVE To explore clinical effects of Tirofiban treatment on patients with high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) after percutaneous coronary intervention (PCI). PATIENTS AND METHODS 107 patients with high-risk NSTE-ACS after PCI were selected and were divided into two groups. One group of 56 patients was treated with Tirofiban and a second group of 51 patients was taken as control. The occurrence conditions of creatine kinase-myoglobin (CK-MB), cardiac troponin1 (cTnI) level, hemorrhage incidents and major adverse cardiac events (MACE) incidents after treatments were compared. RESULTS After 24 h operation, CK-MB and cTnI level in Tirofiban group were both significantly lower than those in control group (p < 0.05), while the difference of hemorrhage incidents between two groups is of no statistical significance (p < 0.05); and the differences in overall occurrence rate of MACE incidents and the occurrence rate of angina pectoris after infarct between two groups were statistically significant (p < 0.05). CONCLUSIONS Tirofiban could improve the blood supply condition of hearts of patients with high-risk NSTE-ACS after emergent PCI, lower the occurrence rate of MACE incidents, and decrease the risk of hemorrhage.
-
2.
Association of cardiovascular emerging risk factors with acute coronary syndrome and stroke: A case-control study.
Martínez Linares, JM, Guisado Barrilao, R, Ocaña Peinado, FM, Salgado Parreño, FJ
Nursing & health sciences. 2016;(4):488-495
Abstract
In this study, we estimated the risk of acute coronary syndrome and stroke associated with several emerging cardiovascular risk factors. This was a case-control study, where an age - and sex-matched acute coronary syndrome group and stroke group were compared with controls. Demographic and clinical data were collected through patient interviews, and blood samples were taken for analysis. In the bivariate analysis, all cardiovascular risk factors analyzed showed as predictors of acute coronary syndrome and stroke, except total cholesterol and smoking. In the multivariate logistic regression model for acute coronary syndrome, hypertension and body mass index, N-terminal section brain natriuretic peptide and pregnancy-associated plasma protein-A were independent predictors. For stroke, the predictors were hypertension, diabetes mellitus, body mass index, and N-terminal section brain natriuretic peptide. Controlling for age, sex, and classical cardiovascular risk factors, N-terminal section brain natriuretic peptide and pregnancy-associated plasma protein-A were independent emerging cardiovascular risk factors for acute coronary syndrome, but pregnancy-associated plasma protein-A was not for stroke. High levels of cardiovascular risk factors in individuals with no episodes of cardiovascular disease requires the implementation of prevention programs, given that at least half of them are modifiable.
-
3.
Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome.
Pérez-Castrillón, JL, Abad, L, Vega, G, Sanz-Cantalapiedra, A, García-Porrero, M, Pinacho, F, Dueñas, A
European review for medical and pharmacological sciences. 2008;(2):83-8
Abstract
OBJECTIVE The aim of this paper is to evaluate the effect of atorvastatin on bone mineral density in patients with acute ischemic heart disease. MATERIAL AND METHODS Eighty-three patients (52 male and 31 female) with acute coronary syndrome were studied. They received treatment with atorvastatin using low doses (20 mg) and high doses (40 mg-80 mg). Initial and final cholesterol, triglyceride, calcium, phosphorus, 25-hydroxyvitamin D were obtained from every patient. Spine and hip bone mineral density were performed at the beginning and one year later. RESULTS Atorvastatin treatment increases vitamin D (33%, p = 0.007) and decreases the individuals with vitamin D insufficiency. Bone mineral density increased in the spine (1.31%, p = 0.02), but it was significant only in male and patients presenting vitamin D levels higher than 30 nmol/l. CONCLUSION Atorvastatin has a beneficial effect on bone metabolism in patients with acute ischemic heart disease (mainly males) by incrementing bone mineral density in which vitamin D levels are required to be higher than 30 nmol/l for the drug to be effective.
-
4.
[T-lymphocyte voltage dependent K(+) channel is upregulated in patients with acute coronary syndrome].
Guo, LF, Zhang, CT, Wu, J, Liu, N, Sun, LP, Liu, J, Ma, J
Zhonghua xin xue guan bing za zhi. 2007;(9):818-21
Abstract
OBJECTIVE To determine current density of voltage-gated potassium channels and Kv1.3 express in T-lymphocyte derived from patients with acute coronary syndrome (ACS). METHODS Peripheral blood mononuclear cells were collected from 12 patients with ACS and 10 control donors. Whole-cell patch clamp technique was used to record the outward K(+) currents (IK) and western blots technique was used to detect the express of Kv1.3 protein in lymphocyte. RESULTS (1) The current density of voltage-gated potassium channel was significantly higher in ACS patients [(269 +/- 94) pA/pF] than in controls [(191 +/- 64) pA/pF, P < 0.01] while membrane capacitance was similar between the two groups. (2) Kv1.3 protein expression was also significantly increased in ACS patients than in controls (P < 0.01). CONCLUSION The lymphocyte voltage-gated potassium channel is upregulated in patients with ACS suggesting a role of Kv activation in the pathophysiology of ACS.